Milford, MA, United States
Milford, MA, United States

Avecia was a privately owned group of biotechnology companies with recognised leading positions in process development and manufacture of biological and oligonucleotide pharmaceuticals, and had their international headquarters in Blackley, Manchester, England.The group's Biologics business, based in Billingham UK, was acquired first by Merck and then subsequently became Fujifilm Diosynth Biotechnologies in April 2011. The group's OligoMedicines business was acquired by Nitto Denko in February 2011, and so the Avecia Group no longer exists as a trading company. The trading name is now used by Nitto Denko Avecia Inc. Wikipedia.


Time filter

Source Type

News Article | November 14, 2016
Site: www.prnewswire.co.uk

MILFORD, Massachusetts, 14 de noviembre de 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) lanzó hoy su progreso en la expansión del desarrollo analítico de la empresa y capacidades de fabricación de oligonucleótidos. El anuncio señala la continuación de la estrategia de crecimiento robusto de Avecia para aumentar significativamente su capacidad de fabricación de sustancias de fármacos oligonucleótidos en Milford, MA junto con la adición de capacidad del producto de fármacos en Irvine, CA y capacidades de desarrollo analítico en Irvine, CA y Marlboro, MA. Avecia, un reconocido líder en la fabricación de ácido nucleico terapéutico, está en etapas avanzadas para construir una nueva planta de fabricación de sustancia de fármacos de oligonucleótidos con capacidad adicional de más de 1,5mol. A principios de este año, un nuevo sintetizador de 300mmol fue puesto en operación con éxito aumentando la capacidad operacional de su tipo de activos. Se prevé que en 2017 el sitio Milford de Avecia tendrá casi 3 mol de oligonucleótidos de capacidad de fabricación de síntesis cGMP operacional incluyendo activos alineados haciéndola la mayor instalación de oligonucleótidos cGMP en el mundo. Según el director general de Avecia, Detlef Rethage, la expansión de 300mmol en 2016 seguido por la nueva instalación de >1,5mol en 2017 ayudará a los clientes a recibir substancia de fármacos de oligonucleótidos oportuna para impulsar programas en ensayos clínicos como estaba previsto. "Avecia está orgulloso de la experiencia e innovación encontrada en Avecia que nos permite traer las nuevas unidades de fabricación online en cuestión de meses en vez de años," dijo Rethage. El personal de laboratorio de desarrollo analítico y de oficina cuenta ahora con una nueva planta de 6.500 pies cuadrados en Marlboro, MA. La instalación de Marlboro se complementó por Nitto Avecia Pharma Services, una nueva compañía creada como resultado de la reciente adquisición de Avecia de Irvine Pharmaceutical Services (Irvine) y Avrio Biopharmaceuticals (Avrio). Nitto Avecia Pharma Services localizado en Irvine, CA aumentó significativamente las capacidades analíticas de Avecia y apoyo de la fabricación de producto farmacéutico. Rethage dijo, "Nitto Avecia Pharma Services es el complemento perfecto para nuestros servicios de sustancia de fármacos de oligonucleótidos y un paso clave en nuestros planes de crecimiento estratégico. Avecia Group ahora ofrece servicios de fabricación y desarrollo en la costa este, costa oeste y en el medio oeste en nuestras instalaciones de Cincinnati." Como parte de su crecimiento planificado, Avecia anticipa que añadirá muchos más empleos a tiempo completo durante los próximos tres meses. Las nuevas posiciones se especializarán en microbiología, química analítica, fabricación, garantía de calidad e ingeniería. Puede encontrar más información sobre las posiciones abiertas en las instalaciones de Avecia en www.aveciacareers.com. Nitto Avecia Inc. es un líder reconocido en servicios de desarrollo y fabricación de ácido nucleico terapéutico con instalaciones ubicadas en Milford, Mass.; Marlboro, Mass.; y Cincinnati  ofreciendo  servicios para ADN, ARN y otros oligonucleótidos basados en terapéuticos desde escala de miligramos a etapa pre-clínica a lanzamiento post-comercial de más de 1000kg. Más información: www.Avecia.com. Nitto Avecia es miembro de Nitto Group. Más información: www.Nitto.com Nitto Avecia Pharma Services es la única solución para contrato premier de servicios de desarrollo y fabricación. Nitto Avecia Pharma Services apoya a las industrias farmacéutica, biofarmacéutica y de dispositivos médicos con un completo paquete de servicios cGMP incluyendo formulación/preformulación, fabricación parenteral, desarrollo analítico, desarrollo biofarmacéutico, química estructural, química analítica, microbiología, almacenamiento de estabilidad y pruebas de dispositivo de entrega de fármacos. Con tres instalaciones de vanguardia ubicadas en un campus de Irvine, CA, el personal experimentado de Nitto Avecia Pharma Services y una infraestructura robusta de calidad ofrece soluciones centradas en el cliente para fase temprana a través de la gestión del ciclo de vida posterior a la comercialización. Más información www.aveciapharma.com


News Article | November 14, 2016
Site: www.prnewswire.co.uk

MILFORD, Massachusetts, Nov. 14, 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) today released its progress in expanding the company's analytical development and oligonucleotide manufacturing capacities. The announcement signals the continuation of Avecia's robust growth strategy to significantly increase its oligonucleotide drug substance manufacturing capacity in Milford, MA along with the addition of drug product capacity in Irvine, CA and analytical development capabilities in Irvine, CA and Marlboro, MA. Avecia, a recognized leader in therapeutic nucleic acid manufacturing, is in advanced stages to build a new oligonucleotide drug substance manufacturing facility with additional capacity of more than 1.5mol. Earlier this year, a new 300mmol synthesizer was successfully taken into operation increasing the operational capabilities of its midscale asset. It is expected that in 2017 Avecia's Milford site will have nearly 3 mol oligonucleotide cGMP synthesis manufacturing capacity operational including aligned downstream assets making it the largest cGMP oligonucleotide facility in the world. According to Avecia's president Detlef Rethage, the 300mmol expansion in 2016 followed by the new >1.5mol facility in 2017 will help clients to receive timely oligonucleotide drug substance to advance programs in clinical trials as planned. "Avecia takes pride that the experience and innovation found within Avecia allows us to bring the new manufacturing units online in a matter of months rather than years," said Rethage. Analytical development laboratory and office personal now staff a new 6,500 square foot facility in Marlboro, MA. The Marlboro facility was complemented by Nitto Avecia Pharma Services, a new company created as a result of Avecia's recent acquisition of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio). Nitto Avecia Pharma Services located in Irvine, CA significantly increased Avecia's analytical capabilities and support of drug product manufacturing. Rethage said, "Nitto Avecia Pharma Services is the perfect complement to our oligonucleotide drug substance services and a key step in our strategic growth plans. Avecia Group now offers manufacturing and development services on the East Coast, West Coast and in the Midwest at our Cincinnati facility." As part of its planned growth, Avecia anticipates it will add many additional full-time jobs over the next three months. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering. More information on open positions at any of the Avecia facilities may be found at www.aveciacareers.com. Nitto Avecia Inc. is a recognized leader in therapeutic nucleic acid manufacturing and development services with facilities located in Milford, Mass.; Marlboro, Mass.; and Cincinnati  offering  services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage  to 1000kg + post commercial launch. More information: www.Avecia.com. Nitto Avecia is proud member of Nitto Group. More information: www.Nitto.com Nitto Avecia Pharma Services is your single solution for premier contract development and manufacturing services. Nitto Avecia Pharma Services supports the pharmaceutical, biopharmaceutical, and medical device industries with a complete package of cGMP services including preformulation/formulation, parenteral manufacturing, analytical development, biopharmaceutical development, structural chemistry, analytical chemistry, microbiology, stability storage and drug delivery device testing. With three state-of-the-art facilities located on one campus in Irvine, CA, Nitto Avecia Pharma Services' experienced staff and robust quality infrastructure delivers client-centric solutions for early phase through post-market life cycle management. Learn more at www.aveciapharma.com


News Article | November 14, 2016
Site: www.prnewswire.co.uk

MILFORD, Massachusetts, 14. November 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) informierte heute über seinen Fortschritt beim Ausbau seiner Fähigkeiten für analytische Entwicklung und Oligonukleotid-Herstellung. Die Ankündigung signalisiert die Fortsetzung der robusten Wachstumsstrategie von Avecia, die Herstellungskapazität seiner oligonukleotiden Arzneimittelsubstanzen in Milford, MA, wesentlich zu erhöhen. Des Weiteren sollen weitere Arzneimittelkapazitäten in Irvine, CA, und analytische Entwicklungsfähigkeiten in Irvine, CA, sowie Marlboro, MA, hinzukommen. Avecia, ein anerkannter, führender Hersteller von therapeutischen Nukleinsäuren, befindet sich in fortgeschrittenen Stadien des Baus einer neuen Produktionsstätte für oligonukleotide Arzneimittelsubstanzen mit einer zusätzlichen Kapazität von über 1,5 mol. Zu Beginn des Jahres wurde ein neuer 300 mmol Synthesizer erfolgreich in Betrieb genommen, wodurch die operativen Kapazitäten seiner mittleren Anlagen erhöht wurden. Es wird erwartet, dass Avecia an seinem Standort in Milford 2017 eine Herstellungskapazität zur cGMP-Synthese von Oligonukleotiden von nahezu 3 mol erreicht, einschließlich der Angliederung nachgelagerter Anlagen, wodurch Avecia zum größten cGMP-Oligonukleotidwerk der Welt wird. Laut Präsident Detlef Rethage von Avecia sorgt die Erweiterung auf 300 mmol in 2016 gefolgt von dem neuen Werk mit einer Kapazität von über 1,5 mol dafür, dass Kunden oligonukleotide Arzneimittelsubstanzen fristgerecht erhalten, um wie geplant Programme in klinischen Studien voranzutreiben. „Avecia ist stolz darauf, dass wir dank unserer Erfahrung und Innovation bei Avecia die neuen Herstellungseinheiten innerhalb von Monaten anstatt von Jahren in Betrieb nehmen können", sagte Rethage. Mitarbeiter des neuen analytischen Entwicklungslabors sowie Büromitarbeiter beziehen derzeit ein neues Werk mit 600 m² in Marlboro, MA. Das Werk in Marlboro wurde ergänzt durch Nitto Avecia Pharma Services, ein neues Unternehmen, das infolge der kürzlichen Übernahme von Irvine Pharmaceutical Services (Irvine) und Avrio Biopharmaceuticals (Avrio) durch Avecia entstand. Durch Nitto Avecia Pharma Services mit Sitz in Irvine, CA, wurden die analytischen Fähigkeiten und die Unterstützung der Arzneimittelherstellung von Avecia wesentlich erhöht. Rethage äußerte: „Nitto Avecia Pharma Services ist die perfekte Ergänzung zu unserem Angebot im Bereich oligonukleotide Arzneimittelsubstanzen und ein wichtiger Schritt für unsere strategischen Wachstumspläne. Die Avecia Group bietet jetzt Herstellungs- und Entwicktlungsdienste an der Ostküste, Westküste und im Mittleren Westen in unserem Werk in Cincinatti an." Als Teil seines geplanten Wachstums erwartet Avecia die Schaffung vieler weiterer Vollzeitstellen in den nächsten drei Monaten. Die neuen Stellen beziehen sich auf Spezialisierungen in Mikrobiologie, analytischer Chemie, Herstellung, Qualitätssicherung und Technik. Weitere Informationen zu Stellenangeboten in Werken von Avecia finden Sie unter www.aveciacareers.com. Nitto Avecia Inc. ist ein anerkannter, führender Hersteller von therapeutischen Nukleinsäuren und bietet Entwicklungsdienste in seinen Werken in Milford, Mass., Marlboro, Mass., und Cincinnati an. Die Angebote umfassen Dienstleistungen für Arzneimittel auf Basis von DNA, RNA und anderen Oligonukleotiden im Milligrammbereich in der präklinischen Phase bis zu 1000 kg nach Markteinführung. Weitere Informationen: www.Avecia.com. Nitto Avecia ist stolzes Mitglied der Nitto Group. Weitere Informationen: www.Nitto.com Nitto Avecia Pharma Services ist Ihre Komplettlösung für führende Vertragsentwicklungs- und Herstellungsdienste. Nitto Avecia Pharma Services unterstützt die pharmazeutischen, biopharmazeutischen und medizintechnischen Industrien mit einem Komplettpaket von cGMP-Diensten, darunter: Präformulierung/Formulierung, parenterale Herstellung, analytische Entwicklung, biopharmazeutische Entwicklung, strukturelle Chemie, analytische Chemie, Mikrobiologie, Stabilitätslagerung und Testen von Arzneimittelabgabesystemen. Mit drei modernsten Werken auf einem Campus in Irvine, CA, liefert Nitto Avecia Pharma Services mit erfahrenen Mitarbeitern und einer robusten Qualitätsinfrastruktur kundenorientierte Lösungen für Lifecyle-Management in den frühen Phasen bis nach der Markteinführung. Weitere Informationen siehe www.aveciapharma.com


News Article | December 9, 2016
Site: www.prnewswire.co.uk

According to a new market research report "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, Biotechnology) - Forecasts to 2021" published by MarketsandMarkets, the global market is expected to reach USD 2.20 Billion by 2021 from USD 1.33 Billion in 2016, at a CAGR of 10.6% during the forecast period. Browse 229 market data Tables and 53 Figures spread through 248 Pages and in-depth TOC on "Oligonucleotide Synthesis Market" Early buyers will receive 10% customization on this report. The global Oligonucleotide Synthesis Market analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. The growth of this market is mainly driven by factors such as increasing R&D expenditure in pharmaceutical and biotechnology companies, increased use in clinical applications and molecular diagnostics, increasing government investments for the development of genomics and evolving significance of RNA-interference oligos in therapeutics and diagnostics are key factors driving market growth for oligonucleotide synthesis. The report segments the Oligonucleotide Synthesis Market based on product and services, applications, end user, and region. On the basis of products and services, the Oligonucleotide Synthesis Market is segmented into synthesized oligonucleotides, reagents, and equipment. Synthesized oligonucleotides are expected to account for the largest share of Oligonucleotide Synthesis Market, in 2016. The growth of the synthesized oligonucleotides segment is attributed to the increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics. The rising demand for custom oligos also contributes to the growth of the synthesized oligonucleotides market. On the basis of application, the Oligonucleotide Synthesis Market is further segmented into research, diagnostic and therapeutic. Research segment is expected to account for the largest share of Oligonucleotide Synthesis Market in 2016. Diagnostic segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is mainly attributed to the emerging application of molecular diagnostics (MDx) and genetic testing. The increasing use of technologies such as DNA microarrays in the analysis of biological samples and developing molecular oncology diagnostics tests also contribute in the growth of molecular diagnostics market. On the basis of end-user, the Oligonucleotide Synthesis Market is categorized into academic research institutes, diagnostic laboratories, pharmaceutical and biotechnology companies, and other end users (private research institutes and hospitals). In 2016, the academic research institutes segment is expected to be the major end-user segment in the Oligonucleotide Synthesis Market. Academic researchers primarily use oligonucleotides for various applications in genetic engineering, polymerase chain reaction (PCR) activities, and high-throughput sequencing. Based on region, the Oligonucleotide Synthesis Market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is expected to account for the largest share of this market in 2016. However, the Asia-Pacific market is expected to grow at the highest CAGR, mainly due to the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. Furthermore, the increasing focus of prominent players on APAC is another factor driving the growth of this market. The Oligonucleotide Synthesis Market is a highly fragmented market, with several big and emerging players. Key market players include Bioautomation Corporation (U.S.), L.G.C Biosearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec S.A (Belgium), GE Healthcare (U.S.), Integrated DNA Technologies (IDT) (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies (U.S.), Nitto Denko Avecia Inc. (U.S.). Next-Generation Sequencing (NGS) Market by Platforms (HiSeq, MiSeq, HiSeq X Ten/X Five, Nextseq500, Ion Proton, PGM, IonS5, PacBio & Sequel), Services (Targeted Sequencing, De novo), & Application (Diagnostic, Drug Discovery) - Global Forecasts to 2021 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


Chen X.-D.,University of Waterloo | Duncan J.S.,Princeton University | Duncan J.S.,Plymouth State University | Verma A.K.,Princeton University | And 2 more authors.
Journal of the American Chemical Society | Year: 2010

The dinuclear precursors Fe2(NtBu)2Cl 2(NH2 tBu)2, [Fe2(N tBu)(S)Cl4]2-, and Fe2(NH tBu)2(S)(N{SiMe3}2)2 allowed the selective syntheses of the cubane clusters [Fe4(N tBu)n(S)4-nCl4]z with [n, z] = [3, 1-], [2, 2-], [1, 2-]. Weak-field iron-sulfur clusters with heteroleptic, nitrogen-containing cores are of interest with respect to observed or conjectured environments in the iron-molybdenum cofactor of nitrogenase. In this context, the present iron-imide-sulfide clusters constitute a new class of compounds for study, with the Fe4NS3 core of the [1, 2-] cluster affording the first synthetic representation of the corresponding heteroligated Fe4S3X subunit in the cofactor. © 2010 American Chemical Society.


A process for the synthesis of phosphorothioate oligonucleotides is provided which comprises assembling an aligonucleotide bound to a solid support in the presence of acetonitrile; prior to cleaving the oligonucleotide from the solid support removing the acetronitrile; and cleaving the oligonucleotide from the solid support. The process is particularly suited to the large scale synthesis of nucleotides. The acetonitrile may be removed from the solid support by one or both to drying and by washing with solvents. Preferred washing solvents compsiring trialkylamines.


News Article | November 14, 2016
Site: www.prnewswire.com

MILFORD, Massachusetts, 14. November 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) informierte heute über seinen Fortschritt beim Ausbau seiner Fähigkeiten für analytische Entwicklung und Oligonukleotid-Herstellung. Die Ankündigung signalisiert die Fortsetzung der robusten...


News Article | November 14, 2016
Site: www.prnewswire.com

MILFORD, Massachusetts, 14 de noviembre de 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) lanzó hoy su progreso en la expansión del desarrollo analítico de la empresa y capacidades de fabricación de oligonucleótidos. El anuncio señala la continuación de la estrategia de crecimiento...


News Article | November 14, 2016
Site: www.prnewswire.com

MILFORD, Massachusetts, 14 novembre 2016 /PRNewswire/ -- Nitto Avecia Inc. (Avecia), a fait part aujourd'hui des progrès de la société liés à l'extension de ses capacités de développement analytique et de production d'oligonucléotides. Cette annonce souligne la poursuite de la solide...

Loading Avecia collaborators
Loading Avecia collaborators